{"id":"ac-regimen","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"80-90","effect":"Alopecia"},{"rate":"30-40","effect":"Mucositis"},{"rate":"5-10","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"40-60","effect":"Infertility/amenorrhea"},{"rate":"1-5","effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL4303689","moleculeType":"Small molecule","molecularWeight":"306.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin is a topoisomerase II inhibitor and intercalating agent that disrupts DNA replication and transcription, while cyclophosphamide is an alkylating agent that cross-links DNA strands. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells. AC is typically used as neoadjuvant or adjuvant therapy in solid tumors.","oneSentence":"AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:40.890Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (early-stage and metastatic)"},{"name":"Lymphomas"},{"name":"Sarcomas"},{"name":"Other solid tumors (as part of combination regimens)"}]},"trialDetails":[{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07484386","phase":"NA","title":"Combined Effects of Niel Asher Technique and Scapular Clock Exercises in Adhesive Capsulitis","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-10-28","conditions":"Adhesive Capsulitis of Shoulder","enrollment":34},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT05959889","phase":"NA","title":"Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-03-01","conditions":"Breast Cancer, Doxorubicin Induced Cardiotoxicity","enrollment":50},{"nctId":"NCT07304011","phase":"PHASE2","title":"Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-12-17","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT07274917","phase":"NA","title":"Stereotactic Radiotherapy Treatment for Treatment-resistant Depression","status":"ENROLLING_BY_INVITATION","sponsor":"Capital Medical University","startDate":"2026-01-26","conditions":"Treatment-Resistant Depression, Depressive Disorder","enrollment":9},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT03879694","phase":"PHASE1","title":"Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":"Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor","enrollment":19},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07327021","phase":"PHASE2","title":"MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2025-11-11","conditions":"TNBC, Triple Negative Breast Cancer, Early Breast Cancer","enrollment":54},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT06535893","phase":"PHASE2","title":"Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer","status":"RECRUITING","sponsor":"Nagoya City University","startDate":"2024-07-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT07197697","phase":"PHASE2","title":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT06155331","phase":"PHASE2","title":"Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-12-01","conditions":"Breast Cancer Stage 2 and 3","enrollment":44},{"nctId":"NCT06027541","phase":"","title":"Young Patients With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT00070564","phase":"PHASE3","title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2003-11","conditions":"Breast Cancer","enrollment":3294},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT05022823","phase":"NA","title":"Exercise and Compression for Lymphedema","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2022-06-29","conditions":"Breast Cancer Related Lymphedema","enrollment":40},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT02397720","phase":"PHASE2","title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-07","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":150},{"nctId":"NCT06190600","phase":"NA","title":"Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Greater Poland Cancer Centre","startDate":"2018-10-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05020860","phase":"PHASE2","title":"Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer","status":"RECRUITING","sponsor":"Baylor Breast Care Center","startDate":"2023-04-18","conditions":"Breast Cancer, Breast Neoplasm, Breast Cancer Female","enrollment":185},{"nctId":"NCT01897441","phase":"NA","title":"Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-06","conditions":"Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer","enrollment":31},{"nctId":"NCT05496491","phase":"NA","title":"Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Larissa University Hospital","startDate":"2022-08-30","conditions":"Rectal Neoplasms","enrollment":84},{"nctId":"NCT05900856","phase":"NA","title":"Effect of Ultrasound Cavitation on Static and Dynamic Balance in Obese Postnatal Women With Diastasis Recti","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-06-09","conditions":"Rectus Diastasis","enrollment":60},{"nctId":"NCT06396390","phase":"PHASE4","title":"Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nesta Clinic","startDate":"2024-08-01","conditions":"IVF, Fertility Issues, Infertility","enrollment":152},{"nctId":"NCT02096588","phase":"PHASE2","title":"Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-05-20","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":34},{"nctId":"NCT06427226","phase":"PHASE2","title":"Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-06-01","conditions":"Doxorubicin Induced Cardiomyopathy, Breast Cancer","enrollment":46},{"nctId":"NCT06367907","phase":"NA","title":"Biological Effects of Schema Therapy","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2021-09-09","conditions":"Personality Disorders","enrollment":120},{"nctId":"NCT01812252","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-08-19","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT06154109","phase":"PHASE2","title":"Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhiyu Wang","startDate":"2023-11-25","conditions":"Triple Negative Breast Neoplasms","enrollment":90},{"nctId":"NCT06121570","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24},{"nctId":"NCT05408780","phase":"PHASE1","title":"A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects","status":"COMPLETED","sponsor":"Cerecin","startDate":"2022-07-14","conditions":"Alzheimer Disease","enrollment":45},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05981014","phase":"PHASE1, PHASE2","title":"Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-08-01","conditions":"Breast Neoplasms","enrollment":196},{"nctId":"NCT04071574","phase":"PHASE1, PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":"Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure","enrollment":200},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT04248998","phase":"PHASE2","title":"Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2020-05-05","conditions":"Triple-negative Breast Cancer","enrollment":30},{"nctId":"NCT05680194","phase":"","title":"Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT01812616","phase":"PHASE1, PHASE2","title":"A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-09","conditions":"Cancer","enrollment":21},{"nctId":"NCT05636644","phase":"","title":"Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Mei Zhang","startDate":"2022-11-04","conditions":"Breast Cancer","enrollment":112},{"nctId":"NCT04211090","phase":"PHASE2","title":"Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-01-15","conditions":"Non-squamous Non-small-cell Lung Cancer, Brain Metastases","enrollment":45},{"nctId":"NCT05595109","phase":"PHASE2, PHASE3","title":"Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-10-28","conditions":"Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities","enrollment":56},{"nctId":"NCT02419742","phase":"PHASE4","title":"Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-18","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT04170465","phase":"PHASE2","title":"Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-10-29","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT00087178","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-05","conditions":"Breast Cancer","enrollment":2722},{"nctId":"NCT04293796","phase":"NA","title":"Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2019-10-08","conditions":"Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB","enrollment":60},{"nctId":"NCT02789657","phase":"PHASE2","title":"Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.","status":"COMPLETED","sponsor":"Brown University","startDate":"2016-11-21","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT01008150","phase":"PHASE2","title":"Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2010-10","conditions":"Breast Cancer","enrollment":141},{"nctId":"NCT01705691","phase":"PHASE2","title":"Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2012-09","conditions":"Breast Cancer, HER2-negative Breast Cancer","enrollment":50},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT00546156","phase":"PHASE2","title":"Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","status":"COMPLETED","sponsor":"Ian E. Krop, MD, PhD","startDate":"2007-10","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT03587103","phase":"NA","title":"Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment: Testing Alternative Antihypertensive Regimens Using ACE-Inhibitors, Calcium Channel Blockers and Diuretics (LIGHT-ACD)","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2019-08-21","conditions":"Hypertension","enrollment":5000},{"nctId":"NCT02065570","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-05-01","conditions":"Crohn's Disease","enrollment":514},{"nctId":"NCT00002542","phase":"PHASE3","title":"Tamoxifen in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1993-07-20","conditions":"Breast Cancer","enrollment":672},{"nctId":"NCT03389295","phase":"PHASE2","title":"Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Xiayun He, MD","startDate":"2010-01","conditions":"Nasopharyngeal Carcinoma","enrollment":118},{"nctId":"NCT00394251","phase":"PHASE2","title":"Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-08-01","conditions":"Breast Cancer","enrollment":197},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT02457039","phase":"NA","title":"Acupuncture Prevents Chemobrain in Breast Cancer Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-10","conditions":"Chemo-brain, Drug-Related Side Effects and Adverse Reactions, Mild Cognitive Impairment","enrollment":93},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT03862144","phase":"PHASE2","title":"NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2016-05-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":150},{"nctId":"NCT02561832","phase":"PHASE1","title":"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2015-11-06","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT00681993","phase":"NA","title":"Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-04","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT00005639","phase":"PHASE1","title":"Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2000-03","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT02607293","phase":"","title":"A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2015-12-31","conditions":"Polycystic Ovary Syndrome","enrollment":1064},{"nctId":"NCT00256243","phase":"PHASE2","title":"Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer","status":"COMPLETED","sponsor":"Rita Sanghvi, Mehta","startDate":"2004-04","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT03444025","phase":"PHASE2","title":"Neoadjuvant Goserelin for Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2018-03","conditions":"Breast Cancer Triple Negative","enrollment":180},{"nctId":"NCT00093795","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-10","conditions":"Breast Cancer","enrollment":4894},{"nctId":"NCT03381417","phase":"PHASE3","title":"Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2016-10-06","conditions":"Breast Cancer Female","enrollment":128},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":"Antineoplastic Combined Chemotherapy Protocols","enrollment":160},{"nctId":"NCT02701517","phase":"PHASE2","title":"Cyclosporine Plus Methotrexate or Alemtuzumab","status":"TERMINATED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2003-09","conditions":"Unrecognized Condition: Mature B or T-cell Neoplasm","enrollment":72},{"nctId":"NCT03358498","phase":"","title":"Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-01","conditions":"β-thalassemia","enrollment":75},{"nctId":"NCT02549534","phase":"","title":"Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-09","conditions":"Peripheral Neuropathy","enrollment":29},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT00041119","phase":"PHASE3","title":"Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-05","conditions":"Breast Cancer","enrollment":3871},{"nctId":"NCT00482391","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-03","conditions":"Breast Cancer","enrollment":95},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT00024102","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Breast Cancer","enrollment":633},{"nctId":"NCT02613026","phase":"PHASE3","title":"Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer","status":"COMPLETED","sponsor":"307 Hospital of PLA","startDate":"2009-07","conditions":"Breast Neoplasms","enrollment":104},{"nctId":"NCT00336102","phase":"","title":"Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2006-04","conditions":"Breast Cancer, Fatigue, Hypothyroidism","enrollment":541},{"nctId":"NCT00801957","phase":"PHASE2","title":"Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-03","conditions":"Atopic Dermatitis","enrollment":260},{"nctId":"NCT00424203","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2006-01","conditions":"Breast Cancer, Cognitive/Functional Effects, Depression","enrollment":40},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00002784","phase":"PHASE3","title":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1996-06","conditions":"Breast Cancer","enrollment":344},{"nctId":"NCT00365365","phase":"PHASE2","title":"Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT01354275","phase":"NA","title":"In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome","status":"TERMINATED","sponsor":"Bulent Haydardedeoglu","startDate":"2009-03","conditions":"PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles","enrollment":300},{"nctId":"NCT00352378","phase":"PHASE3","title":"Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2002-06","conditions":"Breast Cancer","enrollment":209},{"nctId":"NCT00793377","phase":"PHASE3","title":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"","conditions":"Primary Breast Cancer","enrollment":913},{"nctId":"NCT00555516","phase":"PHASE1, PHASE2","title":"A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy","status":"UNKNOWN","sponsor":"Tri-Service General Hospital","startDate":"2007-11","conditions":"Breast Cancer, Chemotherapy, Neutropenia","enrollment":60},{"nctId":"NCT00525642","phase":"PHASE2, PHASE3","title":"Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2003-06","conditions":"Breast Neoplasms, Adjuvant, Chemotherapy","enrollment":603}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":96,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AC regimen","genericName":"AC regimen","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth. Used for Breast cancer (early-stage and metastatic), Lymphomas, Sarcomas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}